Work

Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity

Year: 2025

Type: article

Abstract: Purpose: To compare total retinal blood flow (TRBF) rates before and after retinopathy of prematurity (ROP) treatment with intravitreal bevacizumab using laser speckle contrast imaging (LSCI). Design: A prospective cohort study. Participants: Twenty-five eyes from 14 premature infants in the neonatal intensive care unit receiving intravitreal bevacizumab for treatment-requiring ROP. Methods: Total retinal blood flow was measured using LSCI longitudinally before and after bevacizumab treatment. Subject characteristics and clinical ROP features, including the need for ROP retreatment, were included in regression analysis using generalized estimating equations to account for 2 eyes per subject and longitudinal measures over time. Main Outcome Measures: The main outcome measure was TRBF, which includes components of peak, mean, and dip over the cardiac cycle. Results: = 0.004). Conclusions: We observed lower TRBF after treatment with intravitreal bevacizumab. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Source: Ophthalmology Science

DOI: 10.1016/j.xops.2025.100857